awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34972161-B4D3E49E-CAAA-43D2-A662-37291496C146
Q34972161-B4D3E49E-CAAA-43D2-A662-37291496C146
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34972161-B4D3E49E-CAAA-43D2-A662-37291496C146
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.
P2860
Q34972161-B4D3E49E-CAAA-43D2-A662-37291496C146
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34972161-B4D3E49E-CAAA-43D2-A662-37291496C146
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
095794717e787cc31843e64fd4e8e53f05335420
P2860
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.